-
SAB BIO Reports Full Year 2024 Operating and Financial Results (opens in a new tab)
SAB-142 Phase 1 trial positive topline data announced at KOL event MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the…
-
SAB BIO to Participate in Upcoming Investor Conferences (opens in a new tab)
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel…
-
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 (opens in a new tab)
SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug…
-
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy (opens in a new tab)
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB” or the…
-
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update (opens in a new tab)
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data…
-
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference (opens in a new tab)
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel…
-
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference (opens in a new tab)
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel…
-
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting (opens in a new tab)
SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the…
-
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting (opens in a new tab)
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel…
-
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates (opens in a new tab)
FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024…
-
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes (opens in a new tab)
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company…
-
SAB BIO Appoints Lucy To as Chief Financial Officer (opens in a new tab)
MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company…